NEW YORK

More news

Regeneron Shares Hit New 10-Year High After Eye Drug Gets FDA Priority Review

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) touched a new 10-year high of $49.44 on Monday. The company said the U.S. Food and Drug Administration gave priority review status for its new investigational eye solution to treat neovascular form of age-related macular degeneration, or wet AMD, a disorder that causes vision loss due to abnormal growth of blood vessels.

Donnie Brasco: Fact and Fiction

The ongoing court testimony by former mafia chieftain Joseph Massino in Brooklyn Federal Court brings back into the public eye the tumultuous events of Massino’s career in the Bonanno crime family, including how the family unwittingly brought in an FBI agent named Joe Pistone (disguised as a jewel thief named Donnie Brasco).

Pages

IBT Spotlight

We Help Businesses Find B2B Service Providers They Can Trust.